Fever (Pyrexia)

Table of Contents

  1. Overview
  2. Pathophysiology of Fever
  3. Infectious Causes
  4. Non-Infectious Causes
  5. Fever of Unknown Origin (FUO)
  6. Special Populations — Pediatric Fever
  7. Neutropenic Fever
  8. Measurement and Antipyretics
  9. Connections
  10. References & Research
  11. Featured Videos

Overview

Fever (pyrexia) is defined as a core body temperature of ≥38.0°C (100.4°F) by oral measurement, or ≥38.3°C (101°F) by some clinical definitions. Normal oral temperature ranges from 36.1–37.2°C (97–99°F); rectal temperature runs approximately 0.5°C higher and is considered the gold standard for accuracy; axillary temperature runs approximately 0.5°C lower; tympanic measurements vary with technique. Body temperature also exhibits significant circadian variation, reaching its lowest point around 6 AM and peaking between 4–6 PM. Hyperpyrexia is defined as temperature greater than 41°C (105.8°F) and represents a danger threshold requiring immediate attention.

Fever is critically a regulated response: exogenous and endogenous pyrogens reset the hypothalamic thermostat upward, causing the body to actively generate and conserve heat until it reaches the new set point. This fundamental distinction separates fever from hyperthermia (heat stroke, malignant hyperthermia, neuroleptic malignant syndrome), conditions in which the thermoregulatory mechanism fails entirely and uncontrolled temperature rise occurs. This distinction is clinically essential: antipyretics such as acetaminophen and NSAIDs act by blocking the prostaglandin cascade that resets the hypothalamic thermostat — they are effective in fever but have no effect in true hyperthermia, where the thermostat is not the problem.

A pervasive patient misconception is that fever itself is dangerous to the brain. In otherwise healthy adults, core temperatures below approximately 41.5°C (106.7°F) do not cause neurological injury. Moderate fever represents an active host defense response that evolved over millions of years, not a medical emergency. The urgency in evaluating fever lies in identifying and treating the underlying cause — whether infection, malignancy, inflammatory disease, or drug reaction — rather than in the elevated temperature number itself. Exceptions exist: patients with cardiac disease may not tolerate the associated tachycardia; fever in pregnancy carries fetal risks; and temperatures above 40°C in very young infants or immunocompromised patients warrant aggressive evaluation regardless of clinical appearance.

Back to Table of Contents

Pathophysiology of Fever

The fever cascade begins with exogenous pyrogens — molecular patterns associated with pathogens or tissue damage. Lipopolysaccharide (LPS, endotoxin) from gram-negative bacterial cell walls is the prototypical exogenous pyrogen; lipoteichoic acid serves the same role for gram-positive organisms. Additional triggers include flagellin, viral single-stranded RNA, fungal β-glucan, and tumor-derived cytokines. These molecules are recognized by pattern-recognition receptors (Toll-like receptors, NOD-like receptors) on macrophages, monocytes, Kupffer cells, and dendritic cells throughout the body.

Activated innate immune cells release endogenous pyrogens — a cascade of cytokines including interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). These small proteins are too large to cross the blood-brain barrier in most brain regions, but the hypothalamus is adjacent to the circumventricular organs — the organum vasculosum of the lamina terminalis (OVLT), the area postrema, and the subfornical organ — specialized structures that lack a tight blood-brain barrier and therefore directly sense circulating cytokines.

In the hypothalamic preoptic area, cytokine signals trigger COX-2 upregulation. COX-2 converts arachidonic acid to prostaglandin E&sub2; (PGE&sub2;), which binds EP3 receptors on hypothalamic neurons and resets the thermoregulatory set point upward. The thermoregulatory response is then coordinated: peripheral vasoconstriction reduces heat loss (explaining the chills and cold skin seen as temperature is rising), piloerection occurs, and skeletal muscle shivering increases heat production. Once core temperature reaches the new set point, the vasoconstriction resolves and sweating commences — the subjective experience of “breaking a fever.”

Antipyretics work by blocking COX enzymes: aspirin and NSAIDs irreversibly or competitively inhibit COX-1 and COX-2; acetaminophen has a similar mechanism via COX inhibition plus a possible central cannabinoid pathway. By reducing PGE&sub2; synthesis, they return the hypothalamic set point toward normal. Fever has genuine immunological benefits: neutrophil chemotaxis and killing are enhanced at higher temperatures; T-cell activation increases; bacterial iron acquisition (which requires enzymatic processes optimized at 37°C) is impaired; and many viral pathogens replicate less efficiently above normal body temperature. These observations explain why moderate fever is not automatically treated in otherwise comfortable patients with a clear source.

Back to Table of Contents

Infectious Causes (Most Common)

Bacterial Infections

Viral Infections

Parasitic Infections

Back to Table of Contents

Non-Infectious Causes

Malignancy

Inflammatory and Rheumatologic Causes

Drug Fever

Other Non-Infectious Causes

Back to Table of Contents

Fever of Unknown Origin (FUO)

The classic Petersdorf-Beeson definition (1961, updated) defines FUO as: fever greater than 38.3°C (101°F) documented on multiple occasions; illness duration greater than 3 weeks; and no diagnosis reached despite a comprehensive evaluation. The original criteria required 1 week of inpatient evaluation; contemporary practice accepts a thorough outpatient workup as the threshold before applying the FUO label. Four subcategories are now recognized: classical FUO, nosocomial FUO (develops in hospitalized patient), immune-deficient FUO (in neutropenic patients), and HIV-associated FUO.

Causes of FUO by Category

FUO Systematic Workup

Back to Table of Contents

Special Populations — Pediatric Fever

Fever Without Source (FWS) in Infants — Age-Based Risk Stratification

Febrile Seizures

Return to School / Daycare

Fever greater than 38°C (100.4°F) requires exclusion from group childcare and school settings until the child is afebrile for at least 24 hours without the use of antipyretics. This standard reduces transmission of febrile illness and ensures the child has sufficient energy for the school environment.

Back to Table of Contents

Neutropenic Fever

Neutropenic fever is defined as a single oral temperature of ≥38.3°C (101°F), or a sustained temperature of ≥38.0°C (100.4°F) for at least one hour, in a patient with an absolute neutrophil count (ANC) less than 500 cells/µL, or whose ANC is expected to fall below 500 within 48 hours. It represents a medical emergency. Without prompt initiation of broad-spectrum antibiotics, mortality can reach 20–30%, particularly in patients with prolonged or severe neutropenia (<100 cells/µL).

The MASCC (Multinational Association for Supportive Care in Cancer) Risk Score stratifies patients into low-risk and high-risk groups. Low-risk patients (score ≥21) have no hypotension, no COPD, a solid tumor or hematologic malignancy without prior fungal infection, no dehydration, outpatient status at fever onset, and age under 60. These patients may be candidates for outpatient management with oral antibiotics (ciprofloxacin + amoxicillin-clavulanate). High-risk patients (score <21 — anticipated prolonged neutropenia >7 days, hematologic malignancy, significant comorbidities, or clinical instability) require hospitalization and intravenous broad-spectrum antibiotics.

Initial management protocol: Blood cultures ×2 sets (one peripheral, one from each lumen of an indwelling central venous catheter if present); urinalysis and urine culture; CXR; basic metabolic panel. Broad-spectrum IV antibiotics must be started within 1 hour of presentation. Standard empiric regimen: piperacillin-tazobactam (4.5g IV q6h) OR cefepime (2g IV q8h) OR meropenem (for patients with prior ESBL or Pseudomonas, or with recent hospitalization). Add vancomycin (or daptomycin for VRE) if: hemodynamic instability, MRSA risk factors (prior MRSA, skin/soft tissue infection), radiographic pneumonia, or severe mucositis. De-escalate or discontinue vancomycin after 48–72 hours if no gram-positive pathogen is identified.

If fever persists beyond 4–7 days despite appropriate antibacterial therapy, empiric antifungal therapy should be added — presumed invasive fungal infection (IFI), most commonly Candida or Aspergillus. Agents: micafungin or caspofungin (echinocandins; preferred in patients with prior azole exposure or hepatic dysfunction); voriconazole or isavuconazole for suspected mold infection.

Prophylaxis during periods of anticipated neutropenia: Antibacterial prophylaxis with levofloxacin (500 mg daily) is recommended for patients expected to have severe neutropenia (<100 cells/µL) for >7 days. Antifungal prophylaxis: fluconazole for short-duration neutropenia; voriconazole or posaconazole for allogeneic stem cell transplant recipients or prolonged neutropenia at high risk for mold. G-CSF (filgrastim or pegfilgrastim) reduces the duration and depth of neutropenia post-chemotherapy but does not replace antibiotics once neutropenic fever is established.

Back to Table of Contents

Measurement and Antipyretics

Temperature Measurement Methods

Antipyretics

Should All Fever Be Treated?

Moderate fever (38–39°C) is a physiological defense response with genuine immunological benefits: enhanced neutrophil phagocytosis and killing, augmented NK cell activity, increased T-cell activation and cytokine production, and impaired replication of many bacterial and viral pathogens at supranormal temperatures. No high-quality randomized evidence demonstrates that treating moderate fever in otherwise healthy patients improves clinical outcomes over supportive care. The decision to administer antipyretics should be based on patient comfort (fever causes malaise, myalgia, and subjective distress), risk of dehydration (particularly in children and elderly patients), and the need for clinical reassessment of the patient’s appearance after temperature reduction. Treat aggressively when: temperature exceeds 40°C; the patient has underlying cardiac disease (the associated tachycardia is poorly tolerated); during pregnancy (fetal neural tube risks); seizure history; or when fever-related altered mental status impedes clinical assessment.

Back to Table of Contents

Connections

References & Research

Historical Background

Hippocrates recognized fever as a sign of disease around 400 BCE and proposed that it accompanied the body’s effort to purge harmful excess; Galen elaborated on this framework, associating fever with imbalance of the four humors. The scientific understanding of fever was transformed in 1851 when Carl Reinhold August Wunderlich systematically measured body temperature in tens of thousands of patients and established 37°C as the human normal, while describing the characteristic patterns of fever in different infectious diseases. Harold Petersdorf and Paul Beeson defined fever of unknown origin in their landmark 1961 paper, establishing a clinical framework that remains foundational today.

The molecular mechanisms of fever were elucidated progressively over the latter half of the 20th century. Elisha Atkins and Phyllis Bodel identified endogenous pyrogens as proteins released by leukocytes in the 1960s. Charles Dinarello characterized interleukin-1 (IL-1) as a central endogenous pyrogen through the 1970s and 1980s, work that fundamentally reshaped the understanding of the fever-immune axis. The critical role of prostaglandin E&sub2; in resetting the hypothalamic thermostat, and the specific neural circuits engaged by PGE&sub2; via EP3 receptors, were confirmed and mapped by Clifford Saper and colleagues through the 1990s and 2000s, completing the mechanistic chain from pathogen to hypothalamic thermostat reset to the clinical experience of fever.

Key Research Papers

  1. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore). https://doi.org/10.1097/00005792-196102000-00002 1961;40:1–30.
  2. Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. https://doi.org/10.1179/096805104225005563 2004;10(4):201–222.
  3. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. https://doi.org/10.1001/jama.2016.0287 2016;315(8):801–810.
  4. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. https://doi.org/10.1200/JCO.2000.18.16.3038 2000;18(16):3038–3051.
  5. Subcommittee on Febrile Seizures, American Academy of Pediatrics. Neurodiagnostic evaluation of the child with a simple febrile seizure. Pediatrics. https://doi.org/10.1542/peds.2011-0097 2011;127(2):389–394.
  6. Drekonja DM, Gnadt B, Yoo T, et al. PECARN/STEP validation study for febrile infants. Acad Emerg Med. PMID 37095571 2023.
  7. Knockaert DC, Vanneste LJ, Bobbaers HJ. Fever of unknown origin in elderly patients. J Am Geriatr Soc. https://doi.org/10.1111/j.1532-5415.1993.tb01833.x 1993;41(11):1187–1192.
  8. Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). https://doi.org/10.1097/MD.0b013e318190ba9f 2007;86(1):26–38.
  9. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the IDSA. Clin Infect Dis. https://doi.org/10.1093/cid/ciq109 2011;52(4):e56–e93.
  10. Saper CB, Romanovsky AA, Scammell TE. Neural circuitry engaged by prostaglandins during the sickness syndrome. Nat Neurosci. https://doi.org/10.1038/nn.2739 2012;15(8):1088–1095.
  11. El-Radhi AS. Fever management: evidence vs current practice. World J Clin Pediatr. https://doi.org/10.5409/wjcp.v1.i4.29 2012;1(4):29–33.
  12. Bleeker-Rovers CP, van der Meer JW, Oyen WJ. Fever of unknown origin. Semin Nucl Med. https://doi.org/10.1053/j.semnuclmed.2009.03.006 2009;39(2):81–87.

PubMed Topic Searches

  1. Fever of unknown origin workup
  2. Neutropenic fever management
  3. Febrile seizures in children
  4. Fever mechanism endogenous pyrogens
  5. Adult-onset Still’s disease
  6. Malaria fever diagnosis

Back to Table of Contents